CNSP
$2.26
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, develops anti-cancer drug candidates for the treatment of brain and central nervous system (CNS) tumors.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, develops anti-cancer drug candidates for the treatment of brain and central nervous system (CNS) tumors. The company's drug candidates include TPI 287 and Berubicin, which are in Phase 2 c...
Recent News
CNS Pharmaceuticals upgraded to Buy at Maxim on TPI-287 roadmap
As previously reported, Maxim upgraded CNS Pharmaceuticals (CNSP) to Buy from Hold with a $20 price target The company has pivoted to its oncology asset TPI-287, a blood brain barrier crossing taxane in development initially for recurrent glioblastoma, the analyst tells investors in a research note. Maxim further cites CNS Pharma’s road map for TPI-287, as well as a potential path forward with Berubicin and cash runway into the second half of 2026, as positioning the stock toward a recovery. Pub
CNS Pharmaceuticals reports FY24 EPS ($38.87) vs. ($12,509.11) last year
“Oncology drug development can be complex and challenging, but the GBM patients who live with this devastating condition in the shadow of a significant unmet medical need keep us motivated and determined to succeed. Although our recently announced findings from the primary analysis of our Berubicin study did not meet its primary target, it provided valuable insight and proof in a large dataset that Berubicin is safe, well-tolerated and has activity against GBM, attributes that few compounds have
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP): When Will It Breakeven?
With the business potentially at an important milestone, we thought we'd take a closer look at CNS Pharmaceuticals...